Chemotherapy Options in Neuroendocrine Tumors is the latest video to be released in the OncLive series on Neuroendocrine Tumors. Matthew H. Kulke, MD, Director of the Program in Neuroendocrine and Carcinoid-Tumors at Dana-Farber/Brigham and Women’s Cancer Center in Massachusetts, is the series Moderator. Insights are provided by panelists Jennifer Eads, MD, Case Western Reserve University; Diane Reidy Lagunes, MD, Memorial Sloan-Kettering Cancer Center; Eric H. Liu, MD, Rocky Mountain Cancer Center; and James C. Yao, MD, The University of Texas MD Anderson Cancer Center. The episodes that have been released to date are listed below:
Episode 1: Clinical and Biological Distinctions in Neuroendocrine Tumors
Episode 2: Disease Factors Influencing Initial Treatment Approaches in NETs
Episode 3: Determining Surgical Candidacy in NETs
Episode 4: Symptom Management in Functional NETs
Episode 5: Goals of Therapy with Somatostatin Analogs in NETs
Episode 6: The Role of Surgery in the Management of NETs
Episode 7: Anti-Angiogenesis and mTOR Inhibition in Carcinoid Tumors
Episode 8: Chemotherapy Options in Neuroendocrine Tumors
Read about the $10.67 million SPORE grant awarded to Dr. Sue O’Dorisio and researchers at the Holden Comprehensive Cancer Center at the University of Iowa for NET research through 4 major projects “exploring the genetics of these tumors, their molecular makeup, and how this information can be used to develop new approaches to diagnosis and treatment.”
- Neuroendocrine Tumor Treatment Options Are Growing and include surgery, therapeutic options for symptom control and tumor control, and an emerging radionuclide agent.
Bottom of Form
